<DOC>
	<DOC>NCT00160043</DOC>
	<brief_summary>The purpose of this study is to determine whether the study drug is effective and safe in the treatment of patients with non small cell lung cancer who have already received one platinum based chemotherapy.</brief_summary>
	<brief_title>Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non Small Cell Lung Cancer.</brief_title>
	<detailed_description>The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vatalanib</mesh_term>
	<criteria>Non small cell lung cancer, Stage IIIB or Stage IV One and only 1 prior platinumbased chemotherapy No other uncontrolled concurrent illness Use of highly effective birth control methods in males or females with reproductive potential Previous participation in another trial within the last 4 weeks Surgery within 10 days prior to the start of study treatment Brain metastases Confirmed diagnosis of infection with the human immunodeficiency virus (HIV) Current treatment with warfarin sodium (Coumadin) or similar anticoagulation medication Breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
</DOC>